CCM Duopharma Biotech Bhd (CCMDB) and PanGen Biotech, Inc. have completed their clinical trials for the biosimilar erythropoietin or EPO product which can be used in kidney dialysis.
Recombinant version of EPO is used as the therapeutic agent of all anemia patients, acute anemia in kidney dialysis patients, anemia due to anti-cancer chemotherapy and patients requiring blood transfusion.
CCMDB said through Duopharma
’s investment into the RM18mil joint clinical trials, the latter obtained exclusive licence to package, fill & finish, and distribute the EPO product in Malaysia, Singapore and Brunei.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
